Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer

Anis A. Hamid, Kaspar Willson, Andrew D. Vincent, Babak Tamjid, Margaret Lee, Alice Bergin, Chun Gan, Ainsley Campbell, Josephine Stewart, Carmel Pezaro, Ben Tran, Andrew J. Weickhardt
  • Asia-Pacific Journal of Clinical Oncology, January 2018, Wiley
  • DOI: 10.1111/ajco.12840

The authors haven't yet claimed this publication.

Read Publication


In partnership with: